SpectraScience, Inc. Announces Commencement of Pan-European MORDIS Evaluation on WavSTAT4

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, Aug. 5, 2013 (GLOBE NEWSWIRE) -- SpectraScience, Inc. (OTCQB:SCIE), a San Diego-based medical device company, announced today that it has begun submission of its protocol to participating institutions for the MORDIS (MOdified Resect and DIScard) evaluation. The evaluation, which will be conducted at eight sites across Europe, brings together the foremost gastroenterologists in each of the respective nations to once again validate the clinical efficacy of the WavSTAT4 Optical Biopsy System.

Help employers find you! Check out all the jobs and post your resume.

Back to news